Atlanta Consulting Group Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.32M Buy
1,103
+382
+53% +$390K 0.21% 68
2026
Q1
$663K Sell
721
-86
-11% -$87.2K 0.14% 80
2025
Q4
$867K Buy
807
+69
+9% +$66K 0.2% 62
2025
Q3
$563K Buy
738
+1
+0.1% +$744 0.14% 77
2025
Q2
$575K Sell
737
-5
-0.7% -$3.88K 0.16% 68
2025
Q1
$613K Sell
742
-9
-1% -$7.49K 0.18% 65
2024
Q4
$580K Sell
751
-26
-3% -$21.5K 0.21% 68
2024
Q3
$688K Buy
777
+242
+45% +$218K 0.17% 106
2024
Q2
$484K Buy
535
+66
+14% +$52.8K 0.1% 73
2024
Q1
$365K Buy
+469
New +$334K 0.13% 88

Other funds holding LLY

Atlanta Consulting Group Advisors's LLY Position: Q2 2026 in Review

Atlanta Consulting Group Advisors increased its Eli Lilly (LLY) stake by 53% in Q2 2026, buying an estimated $390K and bringing the position to 1,103 shares worth $1.32M. The position accounts for 0.21% of the portfolio, ranked #68.

Atlanta Consulting Group Advisors first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Atlanta Consulting Group Advisors held 1,103 shares of Eli Lilly worth $1.32M as of Q2 2026.
  • Atlanta Consulting Group Advisors bought 382 Eli Lilly shares in Q2 2026, an estimated $390K.
  • Eli Lilly made up 0.21% of Atlanta Consulting Group Advisors's portfolio in Q2 2026, its #68 holding.
  • Atlanta Consulting Group Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.